White House works to quell quarantine quandary

After New York and New Jersey issued 21-day mandatory quarantine orders for healthcare workers returning from Ebola-affected West African countries – later somewhat dialing back those requirements allowing those people to stay in their homes – the White House stepped in, declaring any such actions must be based on science and not fear.

After New York and New Jersey issued 21-day mandatory quarantine orders for healthcare workers returning from Ebola-affected West African countries – later somewhat dialing back those requirements allowing those people to stay in their homes – the White House stepped in, declaring any such actions must be based on science and not fear.

To make its point, the Obama administration again sent out Dr Anthony Fauci, director of the National Institute of Allergy...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Sanofi/Regeneron’s Dupixent: A First For COPD, But Not The Last

 

The IL-4/13 inhibitor was approved in the US for COPD, a blockbuster-sized indication, but the commercial ramp could take time and several competitors are on its heels.

Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1

 
• By 

As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.